These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28314304)

  • 1. Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
    Lawson BO; Khong HT
    Anticancer Res; 2017 Mar; 37(3):1365-1368. PubMed ID: 28314304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
    Agarwala SS
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
    Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
    J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
    Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
    J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
    Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
    Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
    Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
    Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
    Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
    J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.
    Navid F; Herzog CE; Sandoval J; Daryani VM; Stewart CF; Gattuso J; Mandrell B; Phipps S; Chemaitilly W; Sykes A; Davidoff AM; Shulkin BL; Bahrami A; Furman WL; Mao S; Wu J; Schiff D; Rao B; Pappo A
    Pediatr Blood Cancer; 2016 Jul; 63(7):1207-13. PubMed ID: 27038395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
    J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
    Eggermont AM; Bouwhuis MG; Kruit WH; Testori A; ten Hagen T; Yver A; Xu C
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):671-7. PubMed ID: 19621225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alph-2b (Sylatron) for melanoma.
    Med Lett Drugs Ther; 2011 Sep; 53(1373):76. PubMed ID: 21921873
    [No Abstract]   [Full Text] [Related]  

  • 12. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
    J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.
    Pandit A; Bhalani N; Bhushan BLS; Koradia P; Gargiya S; Bhomia V; Kansagra K
    Int J Infect Dis; 2021 Apr; 105():516-521. PubMed ID: 33713817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
    Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C
    Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409
    [No Abstract]   [Full Text] [Related]  

  • 15. Allergic sensitization to pegylated interferon-α results in drug eruptions.
    Meller S; Gerber PA; Kislat A; Hevezi P; Göbel T; Wiesner U; Kellermann S; Bünemann E; Zlotnik A; Häussinger D; Erhardt A; Homey B
    Allergy; 2015 Jul; 70(7):775-83. PubMed ID: 25831972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
    Mozzillo N; Ascierto P
    Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyrotoxicosis with pegylated interferon alfa-2b.
    Lowndes SA; Asher R; Middleton MR
    Arch Dermatol; 2010 Nov; 146(11):1273-5. PubMed ID: 21079065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?
    Tarhini AA; Kirkwood JM
    J Clin Oncol; 2012 Nov; 30(31):3773-6. PubMed ID: 23008298
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study.
    Ide K; Sato I; Imai T; Hawke P; Yamada H; Kawasaki Y; Masaki N
    Biol Pharm Bull; 2016 Dec; 39(12):2060-2065. PubMed ID: 27645378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
    Bannink M; Kruit WH; Van Gool AR; Sleijfer S; van der Holt B; Eggermont AM; Stoter G; Hengeveld MW
    Psychosomatics; 2008; 49(1):56-63. PubMed ID: 18212177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.